0001209191-16-094212.txt : 20160129
0001209191-16-094212.hdr.sgml : 20160129
20160129171317
ACCESSION NUMBER: 0001209191-16-094212
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160127
FILED AS OF DATE: 20160129
DATE AS OF CHANGE: 20160129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001269021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-244-6864
MAIL ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dier Mardi
CENTRAL INDEX KEY: 0001574591
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35935
FILM NUMBER: 161374414
MAIL ADDRESS:
STREET 1: PORTOLA PHARMACEUTICALS, INC.
STREET 2: 270 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-01-27
0
0001269021
PORTOLA PHARMACEUTICALS INC
PTLA
0001574591
Dier Mardi
C/O PORTOLA PHARMACEUTICALS, INC.
270 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Executive VP and CFO
Common Stock
2016-01-27
4
A
0
13750
0.00
A
13750
D
Stock Option (Right to Buy)
33.49
2016-01-27
4
A
0
55000
0.00
A
2016-01-27
Common Stock
55000
55000
D
Performance Stock Unit
2016-01-27
4
A
0
13750
0.00
A
2020-01-27
Common Stock
13750
13750
D
Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2016, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.
The option shares shall vest as follows: 1/48th of the shares subject to such option shall vest each month after January 1, 2016, subject to Reporting Person's Continuous Service as of each such date.
Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follow: 50% of the PSUs will become vested upon achievement of the Issuer's gross product sales target for Andexanet alfa, and up to 50% of the remaining PSUs may vest subject to the timing of approval of Betrixaban by the United States Food and Drug Administration.
/s/ Mike Ouimette, as attorney-in-fact
2016-01-27